Pembrolizumab plus chemotherapy for first line treatment of oesophageal cancer or HER2-negative gastroesophageal junction adenocarcinoma approved for use in the EU

This approval is for use in combination with platinum and fluoropyrimidine based chemotherapy for locally advanced or metastatic disease with tumours expressing PD-L1 (combined positive score ≥10). Approval was based on data from the Phase 3 KEYNOTE-590 trial.

Source:

Biospace Inc.